Timothy Prickett : $Hepion Pharmaceuticals (HEPA.US)$ 30%+ short int. multi faceted drug candidate currently in phase 2a clinical trials, on track for phase 3 later in q3. Very positive PR end of week heading into their presentation at biomed conference Fri. afternoon. 5-12$ pt by mid-q3 IMO (not financial advice)